CytoAgents Announces Appointment of New Chief Medical Officer

CytoAgents, Inc., a clinical-stage therapeutics company developing a safe, effective treatment (CTO1681) for Cytokine Release Syndrome (CRS), today announced that it has strengthened its leadership team with the appointment of Arthur P. Bertolino MD, PhD, MBA, as Chief Medical Officer. Dr. Bertolino is a seasoned senior pharmaceuticals executive who has led clinical development and business growth for early-stage biotechnology as well as mid-sized and large pharmaceutical companies. Through extensive domestic and international management and drug development experience, including C-level roles in pharmaceuticals and boutique biotechnology, Dr. Bertolino combines science, medicine, and business administration, with leadership acumen and drive to efficiently deliver high-value pharmaceuticals. Dr. Bertolino is highly regarded for his international clinical research and development. Read more >>